Cardiotoxicity of the cancer therapeutic agent imatinib mesylate-Reference-Cited by-同舟云学术

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Published:2006-07-23 Issue:8 Volume:12 Page:908-916
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Kerkelä Risto,Grazette Luanda,Yacobi Rinat,Iliescu Cezar,Patten Richard,Beahm Cara,Walters Brian,Shevtsov Sergei,Pesant Stéphanie,Clubb Fred J,Rosenzweig Anthony,Salomon Robert N,Van Etten Richard A,Alroy Joseph,Durand Jean-Bernard,Force Thomas

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm1446.pdf

Reference49 articles.

1. Van Etten, R.A. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk. Res. 28 (Suppl. 1), S21–S28 (2004).

2. Deininger, M., Buchdunger, E. & Druker, B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653 (2005).

3. Cohen, M.H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).

4. Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M. & Suter, T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105, 1551–1554 (2002).

5. Grazette, L.P. et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44, 2231–2238 (2004).

Cited by 998 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review;Medical Oncology;2024-09-11

2. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway;Biomedicine & Pharmacotherapy;2024-09

3. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment;Drug Design, Development and Therapy;2024-09

4. The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas;Journal of Biological Chemistry;2024-09

5. Endoplasmic reticulum stress in diseases;MedComm;2024-08-26